Paid Clinical Trials Provo
Discover 1,107 paid clinical trials in Provo, Utah. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
A Trial Comparing Unrelated Donor BMT with IST for Pediatric and Young Adult Patients with Severe Aplastic Anemia (TransIT, BMT CTN 2202)A Trial Comparing Unrelated Donor BMT with IST for Pediatric and Young Adult Patients with Severe Aplastic Anemia (TransIT, BMT CTN 2202)
Sponsor:
Boston Children's Hospital
Location:
Code:
NCT05600426
Conditions
Severe Aplastic Anemia
Eligibility Criteria
Sex: All
Age: 0 - 25
Healthy Volunteers: Not accepted
Interventions
cyclosporine
Matched Unrelated Donor Hematopoetic Stem Cell Transplant
horse anti-thymocyte globulin (ATG)
rabbit anti-thymocyte globulin (ATG)
Methotrexate
A Multicenter Trial to Identify Optimal Atezolizumab Biomarkers in the Setting of Recurrent Glioblastoma. The MOAB TrialA Multicenter Trial to Identify Optimal Atezolizumab Biomarkers in the Setting of Recurrent Glioblastoma. The MOAB Trial
Sponsor:
Duke University
Location:
Code:
NCT06069726
Conditions
Recurrent Glioblastoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Atezolizumab
Sterile Amniotic Fluid Filtrate Epidural Injection.Sterile Amniotic Fluid Filtrate Epidural Injection.
Sponsor:
University of Utah
Location:
Code:
NCT04537026
Conditions
Lumbar Spinal Stenosis
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Amniotic Fluid Allograft
Dexamethasone sodium phosphate
A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Disease (MOG-AD)A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Disease (MOG-AD)
Sponsor:
UCB Biopharma SRL
Location:
Code:
NCT05063162
Conditions
Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOG-AD)
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Rozanolixizumab
Placebo
A Study of SGN-PDL1V in Advanced Solid TumorsA Study of SGN-PDL1V in Advanced Solid Tumors
Sponsor:
Seagen Inc.
Location:
Code:
NCT05208762
Conditions
Carcinoma, Non-Small-Cell Lung
Squamous Cell Carcinoma of the Head and Neck
Esophageal Squamous Cell Carcinoma
Ovarian Neoplasms
Melanoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
PF-08046054
pembrolizumab
ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)
Sponsor:
Chimerix
Location:
Code:
NCT05580562
Conditions
H3 K27M
Glioma
Eligibility Criteria
Sex: All
Age: 0 - 70+
Healthy Volunteers: Not accepted
Interventions
Dordaviprone (ONC201)
Dordaviprone (ONC201) + Placebo
Placebo
XL092 in Patients With Metastatic Castration-Resistant Prostate CancerXL092 in Patients With Metastatic Castration-Resistant Prostate Cancer
Sponsor:
University of Utah
Location:
Code:
NCT06568562
Conditions
Metastatic Castration-resistant Prostate Cancer
Eligibility Criteria
Sex: Male
Age: 18+
Healthy Volunteers: Not accepted
Interventions
XL092
A Research Study to Advance the CF Therapeutics Pipeline for People Without ModulatorsA Research Study to Advance the CF Therapeutics Pipeline for People Without Modulators
Sponsor:
Nicole Hamblett
Location:
Code:
NCT06504589
Conditions
Cystic Fibrosis
Eligibility Criteria
Sex: All
Age: 12+
Healthy Volunteers: Not accepted
To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLCTo Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC
Sponsor:
Shanghai Henlius Biotech
Location:
Code:
NCT05468489
Conditions
Extensive Stage Small Cell Lung Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Serplulimab + chemotherapy (carboplatin-etoposide)
Atezolizumab + chemotherapy (carboplatin-etoposide)
A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell MalignanciesA Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
Sponsor:
BeiGene
Location:
Code:
NCT06634589
Conditions
B-cell Malignancy
Relapsed Cancer
Refractory Cancer
B-cell Lymphoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
BGB-16673
Sonrotoclax
Zanubrutinib
Mosunetuzumab
Glofitamab